Hansa Biopharma AB (LTS:0RC7) PB Ratio: (As of Jul. 07, 2026)


LTS:0RC7 Hansa Biopharma AB LTS:0RC7
63 GF Score
Price kr34.48
GF Value kr24.56
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Hansa Biopharma AB's share price is kr34.48. Hansa Biopharma AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.00. Hence, Hansa Biopharma AB's PB Ratio of today is .

The historical rank and industry rank for Hansa Biopharma AB's PB Ratio or its related term are showing as below:

During the past 13 years, Hansa Biopharma AB's highest PB Ratio was 52.69. The lowest was 3.33. And the median was 9.16.

LTS:0RC7's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.99
* Ranked among companies with meaningful PB Ratio only.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hansa Biopharma AB was 109.10% per year. The lowest was -34.90% per year. And the median was 9.90% per year.

Back to Basics: PB Ratio


Hansa Biopharma AB  (LTS:0RC7) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Hansa Biopharma AB PB Ratio Related Terms


Hansa Biopharma AB PB Ratio Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB PB Ratio Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 4.27 0.00 0.00 0.00

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0RC7 vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's PB Ratio falls into.


LTS:0RC7
63GF Score
Hansa Biopharma AB LTS:0RC7
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Hansa Biopharma AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=34.48/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Hansa Biopharma AB (LTS:0RC7) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.48 is trading 40.4% above its estimated GF Value™ of kr24.56. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for LTS:0RC7:

  • PB Ratio:
  • GF Value™: kr24.56 vs. price of kr34.48 (40.4% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0RC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
63GF Score

Get the complete analysis for LTS:0RC7

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.48
Price
kr24.56
GF Value